Price cuts on 1,364 cancer drugs to save Indians ₹3,540 crore annually

Revised maximum retail prices (MRPs) for 1,364 anti-cancer formulations have come into effect, offering significant financial relief to cancer patients across India. According to the Ministry of Pharmaceuticals, 85 pharmaceutical companies have reported new MRPs for medications across 121 different drugs as of November 8, 2026.

The price rationalization is projected to generate annual savings of ₹3,540 crore for consumers, substantially reducing the financial burden associated with cancer treatment. The initiative reflects ongoing government efforts to improve access to essential medicines by making life-saving medications more affordable for Indian patients.

The revised pricing applies across multiple anti-cancer formulations, ensuring broader coverage of commonly prescribed oncology drugs. Industry analysts note that the move balances affordability for patients with the need for companies to maintain viable operations and continue investment in pharmaceutical research and development.

Cancer treatment costs have long been a concern for Indian households, with medication expenses often forcing families into financial hardship. Government interventions on drug pricing aim to ensure that cost does not become a barrier to timely medical intervention and improved health outcomes for cancer patients nationwide.